Abstract
Biomarkers are molecules that can be measured in the body and can reflect disease activity or progression. They can be used to diagnose and monitor disease, predict treatment response, and identify potential therapeutic targets. Several types of biomarkers have been studied in the context of IgA nephropathy, including protein, gene expression, epigenetic, and microRNA biomarkers. Biomarkers have the potential to improve the accuracy and specificity of the diagnosis of IgA nephropathy and predict the disease progression and response to treatment. However, further studies are needed to validate their diagnostic value in larger cohorts of patients and to integrate them into clinical practice. The development of multi-omics approaches that combine different types of biomarkers may provide a more comprehensive understanding of the disease pathogenesis and potential treatments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
